[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allergy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allergy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,53,84,113,142,170,196,225,247,271,293,316,357,374,404,427,451,477,513,533,553,577,601,624],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100593244","phase-3-safety-study-of-viaskin-peanut-patch-in-peanut-allergic-children-1-through-3-years-of-age-comfort-toddlers-100593244",false,"NCT07003919","Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)","A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy With DBV712 250 mcg in 1-through 3-year-old Children With Peanut Allergy","Key Inclusion Criteria:\n\n* Aged 1 through 3 years at Visit 1 (screening).\n* Physician-diagnosed peanut allergy and following a strict peanut-free diet\n* Peanut-specific IgE \\> 0.7 kUA\u002FL.\n* A positive peanut SPT with the largest wheal diameter of ≥ 6 mm at Visit 1 (screening).\n* An ED ≤ 300 mg peanut protein at screening double-blind placebo-controlled food challenge (DBPCFC).\n\nKey Exclusion Criteria:\n\n* Peanut allergic subjects presenting a medical history of severe anaphylaxis to peanut.\n* Severe generalized dermatologic disease involving the proposed treatment application area (interscapular region).\n* Current immunotherapy for any allergen (including food allergy, allergic rhinitis and\u002For insect allergy).\n* History of any immunotherapy for peanut allergy, including Epicutaneous immunotherapy (EPIT), oral immunotherapy (OIT), sublingual immunotherapy (SLIT).\n* Treatment with any monoclonal antibody or biologic immunomodulatory therapy within 6 months prior to Visit 1.\n* Uncontrolled persistent asthma.","ALL","1 Year","3 Years",{"count":20,"type":21},480,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.",[27,28],"Allergy","Peanut Allergy",[30,31,32,33,34,35,36,28,37,38,39],"Peanut hypersensitivity","Epicutaneous Immunotherapy (EPIT)","Epicutaneous","Immunotherapy","Viaskin","Nut and Peanut Hypersensitivity","Food Hypersensitivity","Food Allergy","Nut and Peanut Allergy","Safety Study","RECRUITING","2026-06-17",{"date":43,"type":44},"2026-06-18","ACTUAL",{"date":46,"type":44},"2025-06-24",{"date":48,"type":21},"2028-05",{"name":50,"class":51},"DBV Technologies","INDUSTRY",91,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100638589","logogram-validation-of-allergy-care-flowcharts-in-primary-care-experience-from-occitanie-100638589","NCT07631039","LOGOGRAM: Validation of Allergy Care Flowcharts in Primary Care: Experience From Occitanie","Validation Des Diagrammes de Flux d'Allergies en Soins Primaires : expérience de la région Occitanie","LOGOGRAM","Inclusion Criteria:\n\n* Patients with suspected asthma, anaphylaxis, drug allergy, food allergy, rhinitis and urticaria.\n* Patients aged 1 year or older at inclusion, registered with a health insurance plan.\n* Patient or legal representative of the minor patient who agrees to participate in the research.\n\nExclusion Criteria:\n\n* Adults placed under guardianship or curatorship.\n* Patients already followed by an allergist and\u002For a specialist doctor for their allergies.\n* Patients who participate in a clinical research study relating to an antiallergic medication, immunosuppressant, immunomodulator in the year preceding their consultation visit with the GP.",{"count":62,"type":21},600,[64],"NA","This study, aimed at validating decision trees developed through collaboration between general practitioners and allergists, seeks to provide French data to optimize care pathways for patients with allergic diseases from the primary care level and to reduce the delays and negative consequences associated with incorrect diagnoses. Most patients with allergic conditions are initially seen in primary care, often during exacerbations. Although allergies, in their many clinical forms, account for approximately 6-8% of primary care consultations, clinicians frequently receive little or no formal training in this field and may not be fully aware of the latest evidence, associated risks, or appropriate referral pathways. These gaps can significantly affect the quality of care and patients' quality of life, while also contributing to higher morbidity and mortality. In this context, the European Academy of Allergy and Clinical Immunology established a multidisciplinary task force to transform existing allergy guidelines into simple, practical, and accessible tools to facilitate diagnosis and management in primary care. The group developed five decision trees covering asthma, anaphylaxis, drug allergy, food allergy, rhinitis, and urticaria to support primary care physicians and other non-specialists in managing patients with symptoms suggestive of allergic or hypersensitivity reactions. The results of this project will be directly applicable to the daily clinical practice of general practitioners in France and could serve as a model for replication in other regions and countries, although adaptations may be required depending on national healthcare systems.",[27],[68,69,70,71],"diagnosis","general practitioner","flowchart","care pathway","NOT_YET_RECRUITING","2026-06-02",{"date":75,"type":44},"2026-06-05",{"date":77,"type":21},"2026-09",{"date":79,"type":21},"2030-09",{"name":81,"class":82},"University Hospital, Montpellier","OTHER",10,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":112},"100638442","phase-2-beginning-to-assess-an-appropriate-control-for-oral-food-challenges-in-alpha-gal-syndrome-cofar-13---beacon4ag-100638442","NCT07611435","Beginning to Assess an Appropriate CONtrol for Oral Food Challenges in Alpha-Gal Syndrome (CoFAR-13) - BeACON4AG","Beginning to Assess an Appropriate CONtrol for Oral Food Challenges in Alpha-Gal Syndrome (CoFAR-13)","BeACON4AG","Inclusion Criteria:\n\n1. Able to understand and provide informed consent and\u002For have a parent or guardian able to understand and provide informed consent. Participants 12-17 years old must be able to provide assent\n2. Participants who are willing to complete study procedures and follow-up\n3. Have clinical history consistent with Alpha-gal Syndrome (AGS)\n4. Have alpha-gal-specific Immunoglobin E (IgE) \\>= 0.1KU\u002FL at screening\n5. Report reaction consistent with AGS within the previous 24 months (prior to enrollment)\n6. If with reproductive potential, agree to be abstinent or use an US Food and Drug Administration (FDA) approved method of birth control for the duration of the study\n7. Willing to be trained on the proper use of a device for the self-administration of epinephrine (i.e., autoinjector or intra-nasal spray) and willing to have two doses available for the duration of the study\n\nExclusion Criteria:\n\n1. Unwilling to consume pork (native\u002Fwild type or genetically modified to no longer contain alpha-gal) during Double Blind Food Challenge (DBFC)\n2. Have underlying health conditions suggesting that participants should not undergo an oral food challenge, including conditions that may be exacerbated by oral food challenge or treatment with epinephrine (e.g., history of ischemic heart disease, uncontrolled asthma, or cardiac arrhythmia)\n3. Likely to move away from the study site prior to completion of follow up or do not have regular access to a phone\n4. Have a history of severe anaphylaxis in response to pork or alpha-gal ingestion, defined as neurologic compromise or requiring intubation or cardiovascular compromise defined as myocardial infarction or other clinically significant cardiovascular events\n5. Unwilling or unable to stop use of medications that may interfere with oral food challenge interpretation, reaction, or treatment for 5 half-lives prior to the challenge (e.g., antihistamines, beta blockers, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)\n6. Have used systemic immunomodulators (including biologics and monoclonal antibody therapy) within 6 months before study entry\n7. Have underlying health conditions that may increase the chance of false positive challenges (e.g., inflammatory bowel disease, chronic urticaria, systemic mastocytosis, and mast cell activating syndrome)\n8. Have used systemic steroids within 4 weeks of study entry\n9. Have used any investigational agent within 6 months of study entry\n10. Are on build-up of immunotherapy such as Antigen-based Immunotherapy (AIT), Oral Immunotherapy (OIT), Sublingual Immunotherapy (SLIT), or Epicutaneous Immunotherapy (EPIT)\n11. Have reacted to mammalian products with onset of symptoms within 30 minutes of oral ingestion\n12. Have current, diagnosed, mental illness or current, diagnosed or self-reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements\n13. Are pregnant or plan to become pregnant during the course of the study\n14. Have past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements, and\u002For may impact the quality or interpretation of the data obtained from the study","12 Years","50 Years",{"count":95,"type":21},160,[97],"PHASE2","This is a multisite, randomized, double-blind, controlled cross-over trial with detailed characterization of participants with varying clinical sub-phenotypes of Alpha-gal Syndrome (AGS) who are then evaluated by oral food challenges with alpha-gal Knock Out (KO) pork versus Wild Type (WT) pork. Each participant will serve as their own control and ingest both alpha-gal-KO and WT pork on different days, with a minimum of an 8-day washout period between oral food challenges.\n\nThe primary objective is to determine whether the odds of positive challenges among participants with suspected alpha-gal syndrome are lower with alpha-gal Knock Out (KO) pork as compared to Wild Type (WT) pork during Double Blind Food Challenge (DBFC)",[100,27],"Alpha-Gal Syndrome",[100,102],"Oral Food Challenge","2026-05-29",{"date":73,"type":44},{"date":106,"type":21},"2026-06-15",{"date":108,"type":21},"2032-09-30",{"name":110,"class":111},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",4,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":125,"conditions":126,"keywords":127,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":141},"100593159","direct-oral-challenges-in-private-practice-setting-to-delabeling-children-with-beta-lactam-allergy-100593159","NCT07002814","Direct Oral Challenges in Private Practice Setting to Delabeling Children With Beta-lactam Allergy","Feasibility of Direct Oral Challenges in Private Practice Setting for the Evaluation of Mild Delayed Reactions to Beta-lactams in Children","Betalactaville","Inclusion Criteria:\n\n* Population: Children's age between 0 and 17 years\n* Child who has undergone a direct oral challenge in a private medical practice and a follow-up consultation within 7 to 14 days for suspected delayed allergy to amoxicillin +\u002F- clavulanate or cefpodoxime or cefixime with the following characteristics:\n* delayed reaction (onset \\> 1 hour after treatment start),\n* mild reaction (isolated urticaria or Maculopapular exanthema),\n* Absence of warning signs suggestive of a severe cutaneous adverse reaction (erythroderma, presence of bullae, vesicles, pustules, target lesions, involvement of oral, genital, or ocular mucosa, facial edema, general condition impairment, organ failure, duration \\> 7 days).\n\nExclusion Criteria:\n\n* Informed children or holders of parental authority objecting to the use of patient data in the study.","17 Years",{"count":123,"type":21},200,"OBSERVATIONAL","The purpose of this study is to demonstrate the feasibility of direct oral challenge performed in private practice setting for children with suspected benign delayed allergy to beta-lactams.\n\nThe results of this study could help establish recommendations for conducting direct oral challenge in primary care settings to delabeling children with benign delayed reactions to beta-lactams.",[27],[128,129,130,131],"Beta-lactams","Allerg","Allergology","Direct oral challenge","2026-04-30",{"date":134,"type":44},"2026-05-06",{"date":136,"type":21},"2026-06",{"date":138,"type":21},"2027-06",{"name":140,"class":82},"Assistance Publique - Hôpitaux de Paris",1,{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":150,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":156,"conditions":157,"keywords":158,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":141},"100627379","early-phase-1-lymph-node-examination-in-cat-allergen-immunotherapy-100627379","NCT07447869","LYmph Node eXamination in Cat Allergen Immunotherapy","LYNX: LYmph Node eXamination in Cat Allergen Immunotherapy (ITN102AD)","LYNX","Inclusion Criteria:\n\n1. Participant must be able to understand and provide informed consent\n2. A clinical history of moderate to severe rhinoconjunctivitis symptoms caused by cat exposure, such that exposure is currently, or was historically to the initiation of treatment, interfering with usual daily activities or with sleep, as defined according to the ARIA classification of rhinitis\n3. Skin prick test wheal greater than or equal to 5 mm to standardized cat extract or cat-specific IgE greater than or equal to 0.7 kU\u002FL obtained within 5 years of screening. These can be obtained from medical records if available from the prior 5 years, or at the screening visit if not\n4. Female participants of childbearing potential must have a negative pregnancy test at the screening visit prior to performing study procedures\n5. For participants in the Subcutaneous Immunotherapy (SCIT) cohort, the following inclusion criterion applies as well: A history of at least 1 year of maintenance subcutaneous allergen immunotherapy to cat, with currently ongoing immunotherapy treatments at least every 6 weeks\n\nExclusion Criteria:\n\n1. Inability or unwillingness of a participant to give written informed consent or comply with study protocol\n2. Current household exposure to cat or regular occupational exposure to cat\n3. For participants in No immunotherapy (IT) cohort, any previous immunotherapy treatment with cat allergen\n4. For participants in No IT cohort, any current treatment with any form of allergen immunotherapy\n5. A history of grade 4 anaphylaxis due to any cause as defined by the WAO grading criteria\n6. Partially controlled or uncontrolled asthma as per Global Initiative for Asthma (GINA) guidelines in the 4 weeks prior to screening. Participants may be rescreened once asthma is well-controlled\n7. Severe asthma as defined by GINA guidelines in the previous 12 months\n8. History of emergency visit or hospital admission for asthma in the previous 12 months\n9. History of chronic obstructive pulmonary disease\n10. History of recurrent acute sinusitis, defined as 2 episodes per year for the last 2 years, all of which required antibiotic treatment\n11. History of chronic sinusitis, defined as sinus symptoms lasting greater than 12 weeks that includes 2 or more major factors or 1 major factor and 2 minor factors. Major factors are defined as facial pain or pressure, nasal obstruction or blockage, nasal discharge or purulence or discolored postnasal discharge, purulence in nasal cavity, or impaired or loss of smell. Minor factors are defined as headache, fever, halitosis, fatigue, dental pain, cough, and ear pain, pressure, or fullness\n12. History of disease affecting the immune system such as autoimmune disease (e.g., systemic lupus erythematosus), immune complex disease (e.g., serum sickness), or immunodeficiency, which, in the opinion of the site investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or may impact the quality or interpretation of the data obtained from the study\n13. History of malignancy of any type, excluding basal cell and squamous cell cancers of the skin that only required surgical excision or in situ carcinoma of the cervix study provided that curative therapy was completed at least 12 months prior to informed consent\n14. Any of the following:\n\n    1. Inhaled tobacco, vaping, or use of inhaled illicit substances within 6 weeks of screening\n    2. Receipt of any investigational product within the past 4 months or 5 half-lives (whichever is longer) prior to screening\n    3. Receipt of systemic corticosteroids within 14 days prior to screening\n    4. Receipt of immunoglobulin within 5 months of screening\n    5. Receipt of other blood product within 30 days of screening\n    6. Use of an immunosuppressant or other immunomodulating drug, except for systemic corticosteroids, within 30 days prior to screening\n    7. Use of biologics targeting the human immune system within the past 24 months prior to screening\n    8. Receipt of any vaccination within the past 6 weeks prior to screening\n15. Pregnant, planning a pregnancy during the study, or breast-feeding\n16. Bleeding disorders\n17. BMI \\>= 40\n18. Other anatomic or musculoskeletal abnormalities that would interfere with FNA sampling procedure\n19. History of lymphedema\n20. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the site investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or may impact the quality or interpretation of the data obtained from the study","18 Years","45 Years",{"count":153,"type":21},16,[155],"EARLY_PHASE1","Sixteen eligible cat-allergic participants will be accrued in the study. Eight participants who have been on subcutaneous immunotherapy (SCIT) at maintenance dosing for at least 1 year will be assigned to the SCIT cohort, and 8 participants who have never been on cat immunotherapy will be assigned to the No immunotherapy (IT) cohort. Participants will undergo intradermal cat allergen challenge in bilateral upper arms at baseline (Day 1), will undergo axillary lymph node and peripheral blood sampling at Day 4, and axillary lymph node, peripheral blood, and adenoid and nasal sampling at Week 3.\n\nThe primary objective is to determine the number of analyzable cells from axillary lymph node fine-needle aspiration 3 days and 3 weeks after intradermal cat allergen challenge in two cohorts of cat-allergic participants: those undergoing cat allergen immunotherapy and those who are not receiving this treatment",[27],[159,160,161],"cat allergen","subcutaneous immunotherapy","immunotherapy","2026-04-27",{"date":164,"type":44},"2026-05-01",{"date":166,"type":44},"2026-04-10",{"date":168,"type":21},"2027-01-27",{"name":110,"class":111},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":178,"sex":16,"minAge":179,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":4},"100636155","investigation-of-allergen-sensitization-in-newborn-babies-diagnosed-with-necrotizing-enterocolitis-100636155","NCT07562009","Investigation of Allergen Sensitization in Newborn Babies Diagnosed With Necrotizing Enterocolitis.","Allergy Risk and Sensitization Following Necrotizing Enterocolitis","AlisNEC","Inclusion Criteria:\n\n1. Infants born in our hospital and diagnosed with NEC during the study period.\n2. Age-matched control infants born in our hospital during the same period but without NEC diagnosis.\n3. Written and verbal informed consent obtained from at least one parent.\n\n   \\-\n\nExclusion Criteria:\n\n1. Infants whose parents did not provide written or verbal consent.\n2. Infants with major congenital anomalies.\n3. Infants with chromosomal disorders.\n4. Infants with gastrointestinal malformations (e.g., duodenal atresia, gastroschisis, omphalocele).\n5. Infants diagnosed with immunodeficiency. -",true,"12 Months","24 Months",{"count":182,"type":21},130,[64],"To evaluate the frequency of allergy between 12 and 24 months of age in infants who were treated in the neonatal clinic and had NEC. To investigate the relationship between NEC development and the development of allergy in the later period.",[186,27,187],"Necrotizing Enterocolitis","Preterm","2026-04-24",{"date":164,"type":44},{"date":191,"type":21},"2026-04-01",{"date":193,"type":21},"2028-01-01",{"name":195,"class":82},"Saglik Bilimleri Universitesi",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":16,"minAge":150,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":224},"100588015","phase-4-jack-jumper-ant-venom-immunotherapy-long-term-effectiveness-investigation-100588015","NCT06935890","Jack Jumper Ant Venom Immunotherapy Long-term Effectiveness Investigation","JAVELIN","Eligibility criteria\n\n\\- Any adult (≥ 18 years) who has completed a JJA VIT program at one of the three participating sites.\n\nInclusion Criteria:\n\n1. Completed a continuous program of JJA VIT of between 3 and \\\u003C 6 years duration.\n2. Have ceased JJA VIT for ≥ 18 months but \\\u003C 5 years.\n3. Have the ability to provide informed consent.\n\nExclusion Criteria:\n\n1. Any person \\\u003C 18 years.\n2. Any adult (≥ 18 years) who has not completed a continuous JJA VIT program of duration between 3 and \\\u003C 6 years.\n3. Any adult (≥ 18 years) who has completed a continuous JJA VIT program of duration between 3 and \\\u003C 6 years but ceased JJA VIT \\\u003C 18 months or \\> 5 years ago.\n4. Any person who has a medical condition, that in the opinion of the investigator, may place them at increased risk if they were to have a sting challenge.\n5. Unable to understand study requirements and provide informed consent.",{"count":204,"type":21},100,[206],"PHASE4","Jack Jumper ant (JJA) venom allergy is a uniquely Australian medical condition. It is the leading cause of venom allergy and affects up to three per cent of the population. 70 percent of people with JJA allergy will have another reaction on a repeat sting and this sensitivity appears to persist for many years.\n\nVenom immunotherapy (VIT) has been shown to be a safe and effective treatment in the prevention of severe systemic allergic reactions (anaphylaxis) to future stings. It is currently offered to patients as standard care in Tasmania, South Australia and Victoria. However, whilst JJA VIT has been used for many years, there is a lack of evidence on the long-term benefit of the treatment and how it impacts patient quality of life.\n\nThis trial will offer patients who have completed a JJA VIT program (between 3 and \\\u003C 6-years duration) and have been off-treatment for at least 18-months and \\\u003C 5 years, to have a supervised JJA sting challenge and blood test to assess their JJA venom tolerance level. It will also ask them to complete a set of questionnaires at different timepoints to obtain a history of their exposure and reactions to JJA stings outside of the hospital setting (field stings), and to measure the impact of the completed VIT and knowledge of their sting challenge outcome on their quality of life and their behaviours around auto-injectors.\n\nThese measures will be used to explore the long-term effectiveness of JJA VIT and the impact of a sting challenge post VIT on a patient's quality of life.",[27,33,209],"Venom Allergy",[211,212,213,214],"Jack Jumper Ant","Venom Immunotherapy","Sting challenge","VIT","2026-03-29",{"date":217,"type":44},"2026-03-31",{"date":219,"type":44},"2025-11-25",{"date":221,"type":21},"2029-10",{"name":223,"class":82},"Murdoch Childrens Research Institute",3,{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":178,"sex":16,"minAge":232,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":141},"100426101","understanding-allergies-and-sensitizations-in-healthy-and-allergic-individuals-100426101","NCT04828603","Understanding Allergies and Sensitizations in Healthy and Allergic Individuals","Understanding Allergies","Inclusion Criteria:\n\n* Any individual with possible allergy\n\nExclusion Criteria:\n\n* Patients with special risks attendant to venipuncture will be excluded","1 Week","90 Years",{"count":235,"type":21},2500,"The purpose of this study is to strengthen our ability to accurately diagnose allergies and understand cellular, humoral, genetic components and physiological changes in allergic disease",[27],"2026-03-16",{"date":240,"type":44},"2026-03-17",{"date":242,"type":44},"2007-10",{"date":244,"type":21},"2028-12",{"name":246,"class":82},"Stanford University",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":16,"minAge":255,"maxAge":92,"enrollmentInfo":256,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":258,"conditions":259,"keywords":260,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":270,"locationsCount":141},"100623866","study-of-indoor-air-pollutants-and-their-impact-in-childrens-health-and-wellbeing-100623866","NCT07402200","Study of Indoor Air Pollutants and Their Impact in Children's Health and Wellbeing","Disrupting Noxious Synergies of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing, Using Advanced Intelligent Multisensing and Green Interventions: an Interventional Study in a Sub-group of Schoolchildren","SynAir-G2","Inclusion Criteria:\n\n* Child included in the SynAir-G observational study\n* Child and caregiver(s) willing to follow the study procedures\n* Written informed consent from the child's parents\u002Fguardians\n* For case group, at least one positive answer (yes) to any of the following questions and for control group, negative answers to all the following questions based on the baseline questionnaire administered in the SynAir-G observational study, as shown below.:\n\n  a. General health i. Does your child have any health problems (if yes to asthma, allergic rhinitis \u002Frhino-conjunctivitis, atopic dermatitis)? b. Asthma i. Has your child ever had wheezing or whistling in the chest in the past 12 months? ii. In the past 12 months, has your child's chest sounded wheezy during or after exercise? iii. In the past 12 months, has your child had a dry cough at night, apart from a cough associated with a cold or chest infection? c. Rhinitis i. In the past 12 months has your child had a problem with sneezing, or a runny, or blocked nose when she\u002Fhe DID NOT have a cold or the flu? d. Eczema (both answers yes) i. Has your child had this itchy rash at any time in the past 12 months? If so, has this itchy rash at any time affected any of the following places: the folds of the elbows, behind the knees, in front of the ankles, under the buttocks, or around the neck, ears or eyes? e. Food allergy i. Has your child had diagnosed food allergy during last 12 months?\n* For case group: Diagnosis of asthma\u002Fallergic rhinitis\u002Feczema\u002Ffood allergy (based on SYNAIR-G baseline questionnaire), active during the past year.\n* For control group: absence of diagnosis of asthma\u002Fallergic rhinitis\u002Feczema\u002Ffood allergy (based on SYNAIR-G baseline questionnaire)\n\nExclusion Criteria:\n\n* Child or child's parents\u002Fguardians who:\n\n  1. Refuse to participate in the project \u002F to give informed consent.\n  2. Do not want to follow the protocol procedures.\n  3. Do not read or\u002Fand write in French.\n  4. Plan a long stay outside the region that does not allow them to follow the visit plan.\n  5. The child is not affiliated to the French social security service","8 Years",{"count":204,"type":21},[64],"The goal of this study is to identify and assess in real time the impact of the combined action of various types of air and dust pollutants within a classroom on children's health and quality of life, particularly regarding atopic\u002Fallergic diseases in children, and on potential exposure to pollutants at home.\n\nParticipants will answer questionnaires regarding their health and medications, undergo allergy tests, perform non-invasive lung function tests and check blood oxygen levels.",[27],[261,262,263],"Air pollution","asthma","allergy","2026-02-06",{"date":266,"type":44},"2026-02-11",{"date":268,"type":44},"2026-02-04",{"date":136,"type":21},{"name":81,"class":82},{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":16,"minAge":278,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":292},"100616762","study-to-assess-the-safety-and-effectiveness-of-beltaven-in-patients-with-allergy-to-apis-mellifera-polistes-dominula-or-vespula-spp-100616762","NCT07309822","Study to Assess the Safety and Effectiveness of Beltaven® in Patients With Allergy to Apis Mellifera, Polistes Dominula or Vespula Spp.","Observational Prospective Study to Assess the Safety and Effectiveness of Beltaven® in Patients With Allergy to Apis Mellifera, Polistes Dominula or Vespula Spp","Inclusion Criteria:\n\n* Age 14 years or older at the time of study inclusion.\n* Written informed consent, duly signed and dated by the patient or by the legal representative in the case of minors.\n* Assent form duly signed and dated by the minor, when applicable.\n* Patients with allergy to Apis mellifera, Vespula spp., or Polistes dominula who have experienced a systemic reaction following a hymenoptera sting, either with involvement of multiple organs or exclusively cutaneous.\n* Positive intradermal test (mean wheal diameter ≥ 5 mm) with Beltaven® diagnostic (allergenic extract of Apis mellifera, Vespula spp., or Polistes dominula).\n* Positive specific IgE test from class 1 onwards (≥ 0.35 kUA\u002FL).\n* Patients willing to receive immunotherapy with Beltaven®.\n\nExclusion Criteria:\n\n* Patients with severe cardiovascular diseases, active malignant neoplasms or malignancies in remission within the last 5 years, non-stabilized systemic or organ-specific autoimmune diseases, severe mental disorders, or other relevant chronic diseases that may interfere with the study results.\n* Patients with known allergy to any of the vaccine excipients.\n* Pregnant patients, patients planning to become pregnant during the study period, or breastfeeding patients.\n* Patients who have received hymenoptera immunotherapy within the 5 years prior to inclusion or during the study.\n* Patients who are to receive immunotherapy with another specific allergen different from the investigational treatment during the study period.\n* Patients with confirmed sensitization to two or more hymenoptera species as demonstrated by CAP inhibition testing.\n* Patients with thrombocytopenic purpura and vasculitis, rhabdomyolysis, or renal failure.","14 Years",{"count":280,"type":21},27,"Non-interventional Study to Assess the Safety and Effectiveness Profile of a SCIT Therapy With Beltaven® With Apis mellifera, Polistes dominula or Vespula spp. allergic patients",[27],"2025-12-16",{"date":285,"type":44},"2025-12-30",{"date":287,"type":44},"2025-02-01",{"date":289,"type":21},"2031-12",{"name":291,"class":51},"Probelte Pharma S.L.U.",13,{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":16,"minAge":179,"maxAge":121,"enrollmentInfo":301,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":303,"conditions":304,"keywords":305,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":83},"100614428","study-of-oral-food-challenge-biomarkers-safer-100614428","NCT07279467","Study of Oral Food Challenge Biomarkers (SAFER)","Study of Oral Food Challenge Biomarkers (CoFAR-15)","SAFER","Inclusion Criteria:\n\n1. Parent or guardian must be able to understand and provide written informed consent and participant must be able to understand and provide assent (if applicable)\n2. Are 12 months - 17 years of age during Screening.\n3. Are sensitized to peanut, as demonstrated by one of the following:\n\n   a. A participant-reported reaction to peanut (at any time) deemed by the investigator to be consistent with an IgE-mediated reaction and one of the following within the past 12 months\n\n   i. Positive Skin Prick Test (SPT) to peanut (wheal diameter that is ≥ 3mm larger than saline control) ii. Positive peanut-specific IgE (sIgE; ≥ 0.10 kUA\u002FL) determined by ImmunoCap\n\n   b. An Ara h 2 sIgE ≥ 1.0 kUA\u002FL, measured within the past 12 months\n4. Are currently avoiding peanut\n\nExclusion Criteria:\n\n1. Are pregnant\n2. Are currently receiving treatment or have received treatment within the prior 2 years for peanut allergy\n3. Have a history of life-threatening anaphylaxis to peanut, defined as neurological compromise or requiring intubation\n4. Have received treatment with dupilumab\u002FDupixent® within the prior 2 years, OR treatment with omalizumab\u002FXolair®, other biologics, or systemic immunomodulatory agents within the prior year\n5. Inability to comply with the required aspects of the study protocol\n6. Have past or current medical conditions or findings from the physical examination, not already listed, that, in the judgment of the site investigator, may pose additional risks related to participation in the study, interfere with the participant's ability to comply with study requirements, or impact the quality or interpretation of the study data\n7. Have been treated with oral steroid or beta blockers within 14 days of the Oral Food Challenge (OFC)\n8. Are unable to discontinue medications, as specified in the Protocol CoFAR-15 MOP, for the minimum wash-out periods prior to Skin Prick Test (SPT) or OFC\n9. Have poorly controlled atopic dermatitis (AD) at Screening, per the PI's discretion\n10. Have poorly controlled or severe asthma\u002Fwheezing at Screening, as defined as experiencing or including any of the following:\n\n    1. Meeting the Global Initiative for Asthma (GINA) criteria for uncontrolled asthma\n    2. History of two or more systemic corticosteroid courses within six months of Screening or one course of systemic corticosteroids within three months of Screening to treat asthma\u002Fwheezing;\n    3. Prior intubation\u002Fmechanical ventilation for asthma\u002Fwheezing;\n    4. One hospitalization or ED visit for asthma\u002Fwheezing within six months of Screening;\n    5. Forced expiratory volume in one second (FEV1) \\\u003C80% of predicted or FEV1\u002Fforced vital capacity (FVC) \\\u003C75% of predicted, with or without controller medications (only for participants who are aged seven years or older and are able to perform spirometry);\n    6. Inhaled corticosteroid (ICS) dosing of \\>500 mcg daily fluticasone (or equivalent ICS based on the CoFAR Inhaled Corticosteroid Equivalency Tables MOP)\n11. Refuse blood sample collection during Screening\n12. The SPT performed during Screening is negative to peanut allergen without dilution (wheal diameter that is \\\u003C 3mm larger than saline control).",{"count":302,"type":21},500,"This is a multi-center, mechanistic study. It is designed to learn more about signs in the body, called biomarkers, that might show if someone will have a reaction to peanut during a feeding test. The trial will enroll children ages 12 months to17 years old who are suspected of having an allergy to peanut.\n\nThe primary objective is to identify a biomarker (or a combination of biomarkers) that will predict oral food challenge (OFC) (feeding test) results for participants with suspected peanut allergy.",[27],[37,28,102,306,299,307],"CoFAR-15","Biomarkers","2025-12-10",{"date":310,"type":44},"2025-12-12",{"date":312,"type":21},"2026-04",{"date":314,"type":21},"2027-10-01",{"name":110,"class":111},{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":178,"sex":324,"minAge":150,"maxAge":151,"enrollmentInfo":325,"targetDuration":4,"studyType":22,"phases":327,"briefSummary":328,"conditions":329,"keywords":340,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":141},"100559957","phase-3-vitamin-d-in-pregnancy-for-prevention-of-early-childhood-asthma-100559957","NCT06570889","VItamin D in pregnanCy for prevenTion Of eaRlY Childhood Asthma","VItamin D in pregnanCy for prevenTion Of eaRlY Childhood Asthma (VICTORY)","VICTORY","* Pregnant Danish women before week 26 with blood levels of EPA+DHA above 4.7% of total fatty acids\n* No current vitamin D intake above the recommended 400 IU\u002Fday\n* No endocrine-, heart-, kidney- or auto-immune disorders\n* No disorders requiring treatment with blood thinning medication","FEMALE",{"count":326,"type":21},2000,[24],"The overall aim of the study is to develop a nutritional preventive vitamin D supplementation strategy in pregnancy for early childhood asthma\u002Fpersistent wheeze during the first three years of life as we hypothesize that supplementation in higher doses than recommended could reduce the risk of disease development.",[330,331,332,333,334,27,335,336,337,338,339],"Asthma","Respiratory Tract Infections","Gastrointestinal Infection","Croup","Eczema","Wheezing","Fractures, Bone","Development, Child","Cognition Disorders in Children","Psychiatric Diagnosis",[341,330,342,334,27,343,344,345,346,347],"Childhood","Infections","Development","Psychiatry","Bone development","Cognition","Growth","2025-09-24",{"date":350,"type":44},"2025-09-30",{"date":352,"type":44},"2024-12-20",{"date":354,"type":21},"2033-03",{"name":356,"class":82},"Professor Klaus Bønnelykke",{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":178,"sex":324,"minAge":150,"maxAge":151,"enrollmentInfo":365,"targetDuration":4,"studyType":22,"phases":366,"briefSummary":367,"conditions":368,"keywords":369,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":372,"leadSponsor":373,"locationsCount":141},"100559140","phase-3-fish-oil-in-pregnancy-for-personalized-prevention-of-early-childhood-asthma-100559140","NCT06560255","Fish Oil in pREgnancY for Personalized Prevention of Early Childhood Asthma","Fish Oil in pREgnancY for Personalized Prevention of Early Childhood Asthma (FREYA)","FREYA","* Pregnant Danish women before week 26 with blood levels of EPA+DHA below 4.7% of total fatty acids\n* No planned use of fish oil supplementations\n* No endocrine-, heart-, kidney- or auto-immune disorders\n* No disorders requiring treatment with blood thinning medication",{"count":326,"type":21},[24],"The overall aim of the study is to develop a nutritional preventive fish oil supplementation strategy in pregnancy for early childhood asthma\u002Fpersistent wheeze during the first three years of life as we hypothesize that both supplementations in higher doses than recommended could reduce the risk of disease development.",[330,331,332,333,334,27,335,336,337,338,339],[341,330,342,334,27,343,344,345,346,347],{"date":350,"type":44},{"date":352,"type":44},{"date":354,"type":21},{"name":356,"class":82},{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":178,"sex":16,"minAge":150,"maxAge":4,"enrollmentInfo":381,"targetDuration":18,"studyType":124,"phases":4,"briefSummary":382,"conditions":383,"keywords":387,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":403},"100574647","impaired-type-i-ifn-immunity-due-to-autoantibodies-or-a-genetic-defect-a-prospective-national-cohort-100574647","NCT06762002","Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort","COVIFERON","Inclusion Criteria:\n\n* Age \\>18 years\n* History of carrying 1) auto-Abs against type I IFNs or 2) IEI impairing the response to, or the production of, type I IFNs (IFN-I-IEI)\n* Affiliated to social security\n* Written informed consent\n\nExclusion Criteria:\n\n* Participation to an interventional clinical trial on a pharmacological treatment\n* Clinical condition leading to life expectancy less than 1 year\n* Subject to a legal protection measure (safeguard of justice, curatorship, tutorship)\n* Individuals deprived of freedom",{"count":302,"type":21},"The major role of human genetic factors in the immune response to infections is now well established, particularly for viral infections. In the context of the COVID-19 pandemic, the following results have identified 1) several inborn errors of immunity (IEI) affecting the response or production of type I interferons (type I IFNs) in around 4% of adult patients with severe clinical disease, and 2) the presence of type I IFN-neutralizing autoantibodies (auto-Abs) in around 15% of severe cases, and 20% of deaths. The investigators would like to carry out a longitudinal immunological and clinical follow-up study on a prospective cohort of patients with either a genetic defect affecting the type I IFN-dependent immune response, or anti-IFN-I auto-Abs, to monitor the incidence of infectious and\u002For autoimmune events in these individuals, the evolution of neutralizing power, and the kinetics of auto-Abs. This should lead to a better understanding of the prevention and management of these patients.\n\nThe research design is a national multicenter prospective cohort of adults with 1) anti-IFN-I auto-Abs or 2) IEI- IFN-I, with follow-up from 1 to 4 years. These individuals may be: 1) patients who have or have had clinical disease (related to COVID-19, other viral infections, autoimmune disorders); or 2) \"healthy\" participants (e.g. blood donors, relatives of an IEI patient).\n\nFollow-up will include:\n\n* yearly visits to the Clinical Investigation Center (CIC) or a clinical department with blood sampling;\n* specific visit in case of hospitalization for infectious events or adverse effects of vaccination, exacerbation or new diagnosis of auto-immune disease, new diagnosis of cancer, or SARS-CoV-2 infection whether or not patients are admitted to hospital, with blood sampling.\n\nIn addition, a retrospective \"passive\" follow-up will be implemented through matching with the data from the SNDS (National Health Data System), in order to collect clinical events of and healthcare resource consumption. Moreover, matching with controls adults from the national CONSTANCES cohort, not carrying auto-Abs against type I IFNs nor IEI-IFN-I, will be performed. (ratio 3:1; matching on age (+\u002F- 5 years), gender and geographic region of recruitment). Individuals under long-lasting immunosuppressive or immunomodulatory drugs will not be eligible. Follow-up of controls, which will be carried out as part of the CONSTANCES cohort, will include web-based questionnaires, every 12 months, in addition to linking with SNDS data as already done in this cohort.\n\nInclusion visit:\n\nAfter signing the consent form, the following tests will be performed:\n\n* Demographic characteristics (sex, age, country of birth)\n* Medical history from participant and family member(s) including infectious and auto-immune diseases, cancers and vaccination status and side effects\n* Blood samples for:\n\n  * full blood cell count;\n  * classical autoimmune investigations (anti-nuclear, anti-ENA, native anti-DNA, anti- thyroid antibodies, rheumatoid factor);\n  * immunophenotyping\\*;\n  * auto-Abs against type I IFNs, other cytokines\\*, or other target proteins\\* (dosage and neutralization activity);\n  * Genetic explorations by whole-exome or whole-genome sequencing\\*;\n  * Biobanking (DNA, plasma\u002Fsera; cryopreserved peripheral blood mononuclear cells (PBMCs).\n\n    * these biological analyses will be carried out as part of dedicated COVIFERON RHU5 workpackages.\n\nIn addition, vaccination against SARS-CoV-2 and influenza will be offered to these subjects as a priority, as part of their usual care.\n\nFollow-up visits :\n\nAnnual visits to the CIC :\n\n* Medical history since last visit, including infectious, auto-immune and oncologic events, vaccination status and side effects\n* Blood samples for:\n\n  * full blood cell count;\n  * classical autoimmune investigation (anti-nuclear, anti-ENA, native anti- DNA, anti-thyroid antibodies, rheumatoid factor);\n  * immunophenotyping;\n  * Auto-Abs against type I IFNs, other cytokines, or other target proteins (dosage and neutralization)\n  * Biobanking (DNA, plasma, cryopreserved peripheral blood mononuclear cells (PBMCs))\n\nAdditional specific visit in the event of a clinical event of interest, at any time during follow-up:\n\n* In case of SARS-CoV-2 infection, whatever the severity of the disease: blood sampling for determination and neutralization of type I anti-IFN autoAbs, CBC, and biobanking (plasma and PBMC) and teleconsultation with the CIC in charge of patients, as soon as possible.\n* In the event of hospitalization for infectious events or exacerbation or new diagnosis of an auto-immune disease: blood sampling for determination and neutralization of anti-IFN-I autoAbs, CBC, and biobanking (plasma and PBMCs) and collection of the hospitalization report in the case report form on a dedicated page.",[384,27,385,386],"Immunology","Genetic Diseases","Infectious Diseases",[388,389,390,391,392],"covid-19","auto-immunity","Type I interferon","kinetics","infectious diseases","2025-09-02",{"date":395,"type":44},"2025-09-08",{"date":397,"type":44},"2025-04-09",{"date":399,"type":21},"2029-01",{"name":401,"class":402},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",9,{"id":405,"slug":406,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":11,"sex":16,"minAge":411,"maxAge":18,"enrollmentInfo":412,"targetDuration":4,"studyType":22,"phases":413,"briefSummary":414,"conditions":415,"keywords":416,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":425,"locationsCount":141},"100561007","phase-2-lace-lactobacillus-paracasei-lpb27-on-early-childhood-eczema-100561007","NCT06584552","LaCE (Lactobacillus Paracasei LPB27 On Early Childhood Eczema)","Lactobacillus Paracasei LPB27 On Early Childhood Eczema","Inclusion Criteria:\n\n* Age: 3 months to 3 years old\n* Diagnosis: Eczema (atopic dermatitis) diagnosed clinically by a paediatric dermatologist or immunologist.\n* Severity: Investigator Global Assessment for Atopic Dermatitis (IGA) severity of 1-3 (almost clear, mild, moderate) and a SCORAD score greater than 8.7.\n* Willingness and ability of the subject to comply with the protocol requirements.\n\nExclusion Criteria:\n\n* Patients on systemic immunosuppression and\u002For biologic agents (participants who start systemic immunosuppression and\u002For biologic agents mid-way through the study will be considered to have not achieved treatment success and will be withdrawn, regardless of their SCORAD index scores).\n* Mothers who are breastfeeding and on probiotics but not willing to stop probiotics.\n* Child already on probiotics and parents not willing to stop during the entire study period (washout period of 4 weeks; including formulas that contains probiotics).\n* Eczema complicated by active skin infection e.g. impetigo\u002Fcellulitis\u002F eczema herpeticum (can be considered once active infection resolved).\n* Child currently on oral or IV antibiotics (washout period of 4 weeks allowable once antibiotics completed). Participants who require antibiotics after being enrolled in the study may continue on the study as usual.\n* Immunodeficient disorders.\n* Chronic disorder involving the gastrointestinal tract (e.g., inflammatory bowel disease, short gut syndrome, cystic fibrosis).\n* Known hypersensitivity to components contained in study product.","3 Months",{"count":204,"type":21},[97],"The LaCE study is a double-blind, randomised, placebo-controlled trial examining the effectiveness of the probiotic Lactobacillus paracasei LPB27 in treating eczema in young children.",[334,27],[384,417,418],"Microbiome","Paediatrics","2025-05-28",{"date":421,"type":44},"2025-06-03",{"date":423,"type":44},"2024-11-15",{"date":77,"type":21},{"name":426,"class":82},"The University of New South Wales",{"id":428,"slug":429,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":11,"sex":16,"minAge":150,"maxAge":434,"enrollmentInfo":435,"targetDuration":4,"studyType":22,"phases":437,"briefSummary":438,"conditions":439,"keywords":440,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":449,"locationsCount":141},"100442549","contribution-of-nasal-ige-production-to-the-boost-of-systemic-allergen-specific-ige-upon-nasal-allergen-contact-100442549","NCT05042830","Contribution of Nasal IgE Production to the Boost of Systemic Allergen-specific IgE Upon Nasal Allergen Contact","Contribution of Local Nasal IgE Production to the Boost of Systemic Allergen-specific IgE Production Upon Nasal Allergen Contact - an Explorative Pilot Study","Inclusion Criteria:\n\n* Birch pollen sensitized subjects\n\n  * Moderate to severe allergic rhinitis to birch pollen allergen for at least two seasons according to their medical history\n  * Sensitization to Bet v 1 (Bet v 1 specific IgE: 3.5 kU\u002FL or higher as specified by UniCAP-FEIA)\n* CD203c or CD63 upregulation upon challenge with Bet v 1 in flow cytometric basophil activation tests (≥20% upregulation of CD63 or CD203c upon Bet v 1 stimulation in comparison with unstimulated controls as measured by flow cytometry)\n* Willingness to follow the protocol.\n* Written informed consent\n* Standard healthcare insurance\n* Subjects should be available during the entire study period\n\nExclusion Criteria:\n\n* Evidence of acute, chronic, malignant or general diseases- assessed by asking the patient (e.g. Did you suffer or are you currently suffering from any malignant or generalised disease? Did you suffer or are you currently suffering from any chronic disease? Did you have any acute disease in the past two weeks?).\n* A History of anaphylaxis.\n* Utilization of leukotriene modifiers.\n* Utilization of long-acting antihistamines.\n* Chronic or intermittent use of oral, inhaled, intramuscular, intravenous, and potent topical corticosteroids.\n* Nasal polyps, history of chronic sinusitis or considerable deviation of the nasal septum\n* Rhinitis secondary to other causes.\n* Contra-indications to skin prick testing, for example, skin irritation in the test area and urticaria factitia.\n* Cardiovascular diseases or anti-hypertensive therapy and beta-blockers.\n* Any disruption of coagulation system through medication or known clotting disorders\n* Prophylactic aspirin therapy\n* Chronic use of additional medications that would affect assessment and the results of the study (e.g., tricyclic antidepressants that block both H1 and H2 receptors)\n* Pregnant or breastfeeding females.\n* Actual disability that would influence subject's ability to participate in the study.\n* History of mental illness, intellectual deficiency, drug or alcohol abuse\n* Active asthma requiring treatment\n* Birch Pollen allergen immunotherapy\n* Arranged travel outside the study region for a substantial portion of study period.","60 Years",{"count":436,"type":21},30,[64],"IgE-associated allergies are consistently on the rise forming an enormous wellbeing concern and affecting about 25% of the population around the world, with main prevalence in developed nations. Birch pollen is one important allergen driving allergic conjunctivitis and rhinitis. The characteristics and location IgE producing cells in the nose and their contribution to the subsequent increase in allergen-specific IgE levels in the serum have so far poorly been investigated. Understanding these mechanisms is critical for the development of new therapeutic approaches and is thus the aim of the proposed study. Thus, the investigators plan to conduct a two-armed study of a randomized placebo-controlled double-blind nasal allergen provocation where 30 patients will be provoked with birch pollen extract (n=20) or placebo (n=10) out of the birch pollen season (October) and follow them closely for up to 4 months. Therefore, the objective of this study is to investigate the localization and characteristics of IgE producing cells in the nasal mucosa contributing to the allergen-induced boosts of specific serum IgE upon natural and controlled nasal allergen exposure.",[27],[441,442],"Hypersensitivity","Immunological Diseases","2025-05-06",{"date":445,"type":44},"2025-05-07",{"date":447,"type":44},"2021-11-11",{"date":77,"type":21},{"name":450,"class":82},"Medical University of Vienna",{"id":452,"slug":453,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":458,"targetDuration":460,"studyType":124,"phases":4,"briefSummary":461,"conditions":462,"keywords":465,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":141},"100530909","epap-interviewstudy-100530909","NCT06192914","EPAP, Interviewstudy","Prospective Survey of the Repeated Occurrence of Anaphylactic Reactions in Patients with Food Allergies","Inclusion Criteria:\n\n* anaphylactic reaction to peanuts, other legumes, tree nuts, seeds (e.g. sesame seed, sunflower seed), cereals (e.g. wheat, oat) or pseudocereals (e.g. quinoa)\n* participation in the European Anaphylaxis Registry (Clinical Trials Identifier: NCT05210543)\n* possibility and consent to receive links to the follow-up electronic surveys via e-mail and fill out the questionnaires electronically\n\nExclusion Criteria:\n\n* if inclusion criteria are fulfilled there are no further exclusion criteria",{"count":459,"type":21},322,"2 Years","The goal of this observational study is to learn about repetitive anaphylactic reactions in food allergic patients and to compare the frequency of repetitive reactions between different elicitors in food allergic patients. The main question it aims to answer are:\n\n• Is there an elicitor specific difference in the occurrence of anaphylactic reactions once the elicitor has been identified and the patient received counselling about its avoidance?\n\nParticipants will answer questionnaires via a link they will receive via e-mail at baseline and 3, 6, 12 and 24 months after inclusion in the study.",[37,463,27,464],"Food Allergy Peanut","Anaphylactic Shock",[37,466,467],"Repetitive Reactions","Quality of Life","2025-02-11",{"date":470,"type":44},"2025-02-13",{"date":472,"type":44},"2022-03-01",{"date":474,"type":21},"2029-02-28",{"name":476,"class":82},"Charite University, Berlin, Germany",{"id":478,"slug":479,"hasResults":11,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":178,"sex":16,"minAge":17,"maxAge":485,"enrollmentInfo":486,"targetDuration":4,"studyType":22,"phases":488,"briefSummary":489,"conditions":490,"keywords":497,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":512},"100546126","nationwide-research-on-the-rewilding-of-kindergarten-yards-100546126","NCT06390878","Nationwide Research on the Rewilding of Kindergarten Yards","Nationwide Research on the Rewilding of Kindergarten Yards - Vahvistu","Vahvistu","Inclusion Criteria:\n\n* Attendance in kindergarten\n\nExclusion Criteria:\n\n* Use of antibiotics in the year before sampling","5 Years",{"count":487,"type":21},320,[64],"Biodiversity is essential for nature and human well-being. Land use has reduced biodiversity in cities that is associated with altered commensal microbiota and a rising burden of immunological disorders among urban children.\n\nThe investigators will estimate how rewilding of kindergarten yards affects commensal microbiome, prevalence of allergies, asthma, atopic dermatitis and infections, cortisol levels, cognitive skills and plasma cytokine levels of children.\n\nOur specific aims are:\n\nTo assess if rewilding diversifies health-associated skin, saliva and gut microbiota and reduces infectious diseases and atopic or allergic symptoms.\n\nAssess whether the rewilding has positive effects on cognitive skills. Assess whether the rewilding changes cortisol and plasma cytokine levels. The investigators will recruit altogether 320 (160 per treatment) study subjects aged between 1-5 to questionnaire study (Task 2), from which 120 study subjects will be analyzed more detailed using microbiological and blood samples (Task 1).",[491,492,493,27,494,495,496],"Microbial Colonization","Atopic Dermatitis","Asthma in Children","Cognitive Change","Respiratory Infection","Nature, Human",[498,499,500,501,502],"Commensal microbiome","Atopy","Planetary health","Biodiversity","Cognitive skills","2024-06-20",{"date":505,"type":44},"2024-06-24",{"date":507,"type":44},"2024-05-15",{"date":509,"type":21},"2027-08-30",{"name":511,"class":402},"Natural Resources Institute Finland",2,{"id":514,"slug":515,"hasResults":11,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":178,"sex":16,"minAge":150,"maxAge":520,"enrollmentInfo":521,"targetDuration":4,"studyType":22,"phases":522,"briefSummary":518,"conditions":524,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":531,"locationsCount":4},"100368017","phase-1-relative-bioavailability-study-to-evaluate-cetirizine-hcl-gummy-10-mg-and-cetirizine-hcl-oral-tablets-10-mg-100368017","NCT04071821","Relative Bioavailability Study to Evaluate Cetirizine HCl Gummy 10 mg and Cetirizine HCl Oral Tablets 10 mg","A Randomized, Open-Label, Single-Dose, Five-Period Crossover, Relative Bioavailability Study to Evaluate Cetirizine HCl Gummy 10 mg and Cetirizine HCl Oral Tablets 10 mg Administered in Healthy Adult Male and Female Subjects","Inclusion Criteria:\n\n1. Are capable of giving informed consent and complying with study procedures;\n2. Male or female, 18 to 55 years of age, inclusive, at date of consent;\n3. Body mass index (BMI) ≥ 18.0 to ≤ 32.0 kg\u002Fm2 and total body weight \\> 50 kg (110 lbs.) at Screening;\n4. All female subjects must have a negative pregnancy test at Screening and at each Check-in Visit; and one of the following:\n\n   1. Using a medically acceptable form of birth control for at least 1 month prior to first dose \\[e.g., hormonal contraceptives (oral, patch, injectable or vaginal ring), intrauterine device, or a double barrier method (e.g., diaphragm, cervical cap, oral, patch or vaginal hormonal contraceptive, condom, spermicide, or sponge)\\]\n   2. Documented as surgically sterile by hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation\u002Ftubal occlusion) at least 6 months prior to the first dose;\n   3. Postmenopausal (no menstruation for a minimum of 12 months and confirmed by FSH and estradiol at Screening);\n5. Medically healthy based on medical history, vital sign measurements, clinical laboratory test results, and physical examination;\n6. Non-smokers (including nicotine-containing products) for at least 6 continuous months prior to the first dose.\n7. Be willing and able to consume all contents of the standardized high calorie, high fat breakfast within 30 minutes prior to dosing.\n\nExclusion Criteria:\n\n1. Females who are pregnant, lactating, or planning to become pregnant during the study;\n2. Life-time history and\u002For recent evidence of alcohol or drug\u002Fsubstance abuse disorder;\n3. Subjects with history of hypersensitivity to cetirizine or hydroxyzine, or any component of the test and reference formulations;\n4. Subjects who test positive at Screening for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), or Hepatitis C virus (HCV) antibody;\n5. Subjects who test positive at Screening or at Check-in for alcohol and\u002For drugs of abuse;\n6. Subjects who donated ≥ 500 mL of blood within 56 days prior to the first dose of study drug or ≥ 50 mL and ≤ 499 mL of blood within 30 days or plasma (e.g. plasmapheresis) within 14 days prior to the first dose of study drug;\n7. Use of prescription or non-prescription drugs, dietary supplements, or herbal supplements at the time of Screening and within 14 days prior to the first dose of the study drug;\n8. Subjects who have a history of difficulty in donating blood or difficulty with phlebotomy procedures, and poor venous access;\n9. Subjects who have participated in another clinical trial within 30 days prior to the first study period;\n10. Member or first-degree relative of study staff or the Sponsor directly involved in the study;\n11. Any condition which in the opinion of Investigator would interfere with the subject's ability to provide informed consent, comply with study instructions, confound interpretation of study results, or endanger the subject if he or she took part in the trial.","55 Years",{"count":436,"type":21},[523],"PHASE1",[27],"2024-06-12",{"date":527,"type":44},"2024-06-13",{"date":529,"type":21},"2025-05-01",{"date":350,"type":21},{"name":532,"class":51},"Seattle Gummy Company",{"id":534,"slug":535,"hasResults":11,"nctId":536,"briefTitle":537,"officialTitle":537,"acronym":538,"eligibilityCriteria":539,"healthyVolunteers":11,"sex":16,"minAge":150,"maxAge":4,"enrollmentInfo":540,"targetDuration":4,"studyType":22,"phases":541,"briefSummary":542,"conditions":543,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":141},"100427126","hemp-seed-awareness-100427126","NCT04841954","Hemp Seed Awareness","ARCHANGE","Inclusion Criteria:\n\n* Major patient\n* Patient referred to the Allergology Unit of the Hospital of Angers, in consultation or in Hospitalization - for conducting prick-tests\n* Patient affiliated or beneficiary of a social security scheme\n* Patient with informed consent\n\nExclusion Criteria:\n\n* Pregnant women, parturients\n* Persons deprived of liberty by administrative or judicial decision\n* Persons receiving psychiatric care under duress\n* Adults under legal protection measure\n* People out of state to express consent\n* people not able to understand French language\n* Patients whose skin reactivity prevents interpretation of tests (patients who cannot interrupt anti-histamines or have severe eczema)",{"count":62,"type":21},[64],"Hemp is a plant of the Cannabaceae family. Cannabis sativa, derived from female flowers, is the first illicit substance used by adolescents and is a major public health problem. Its psycho-active effects come from tetrahydrocannabinol (THC).\n\nUnlike recreational cannabis, industrial hemp derived from cannabis sativa has a high level of cannabidiol (CBD) but a negligible level of tetrahydrocannabinol. Its seeds are now consumed in various forms and generate increasing interest. Seeds have many nutritional benefits.\n\nIt seems important to take an interest in hemp, given the recent expansion of medical cannabis and the increasing use of cannabis for recreational purposes. It is incriminated in various allergies (contact dermatitis, asthma, rhinoconjunctivitis) but also in the occurrence of anaphylaxis to certain foods by cross-allergy in atopic subjects, in association with an Lipid-Transfer Proteins (LTP protein), present in the flower of Cannabis sativa.\n\nUnlike the allergy to recreational cannabis, the allergenicity of hemp seeds is little studied.\n\nHemp seed can cause severe anaphylactic reactions. In all reported cases, the prick-tests were positive for the seeds. Often, patients had never been in contact with hemp seeds but had already been exposed to cannabis by respiratory or manual routes.\n\nThe investigators hypothesize that sensitization by the skin or respiratory route (cannabis smokers, passive exposure to cannabis, workers exposed to hemp, etc.) could lead to the development of a food allergy to hemp seed.",[27],"2024-06-10",{"date":546,"type":44},"2024-06-11",{"date":548,"type":44},"2021-06-01",{"date":550,"type":21},"2025-05-31",{"name":552,"class":402},"University Hospital, Angers",{"id":554,"slug":555,"hasResults":11,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":178,"sex":16,"minAge":561,"maxAge":561,"enrollmentInfo":562,"targetDuration":4,"studyType":22,"phases":563,"briefSummary":564,"conditions":565,"keywords":566,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":141},"100497537","phase-4-non-specific-effects-of-a-modified-measles-vaccination-schedule-to-prevent-allergy-and-unrelated-infection-in-children-100497537","NCT05758532","Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children","Harnessing the Beneficial Non-specific Effects of Measles-mumps-rubella Vaccine in Children on Infection With Unrelated Pathogens and Allergic Diseases - a Single-centre Phase IV RCT With a Factorial Design","NEMAU","Inclusion Criteria:\n\n1. Informed Consent as documented by signature\n2. 6-month-old children\n3. In overall good health, without any clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.) and no clinically significant abnormal finding on history and\u002For physical examination\n4. Fully immunised for age according to the Swiss vaccination schedule\n\n   1. with at least 2 doses of DTP-containing vaccine\n   2. the last dose of vaccine received at least 2 weeks prior to enrolment\n\nExclusion Criteria:\n\n1. Contra-indications to MMR, including\n\n   1. immunosuppression (i.e. proven, suspected, or planned)\n   2. allergy to a component of the vaccine\n   3. receipt of a live-attenuated vaccine in the four weeks prior to inclusion\n2. Vaccine refusal\n3. Indication for an early MMR vaccination, including\n\n   1. Measles outbreak\n   2. Planned immunosuppression (indication to an accelerated schedule to be completed before starting an immunosuppressive treatment)\n   3. Travel to a region with a high risk of measles outbreak\n4. Indication for vaccination with MMR-varicella (MMRV) instead of MMR, including\n\n   1. severe eczema\n   2. parental will\n5. Parental inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, known\u002Fsuspected non-compliance, substance abuse, etc.\n6. Plan to move out of the country or have prolong absence during the trial\n7. Other sibling included in the trial (in the case of multiple pregnancy, only one child can be randomised)\n8. Any temporary contra-indication to MMR, including child being sick (active significant illness, inclusion can be delayed a few days until the illness resolves)","6 Months",{"count":302,"type":21},[206],"The goal of this clinical trial is to evaluate the off-target\u002Fnon-specific effects of the measles-mumps-rubella (MMR) vaccine in children.",[331,342,27,334],[567],"Non-specific\u002Foff-target effect of vaccine","2024-05-27",{"date":570,"type":44},"2024-05-29",{"date":572,"type":44},"2023-03-17",{"date":574,"type":21},"2026-12",{"name":576,"class":82},"Laure Pittet, MD-PhD",{"id":578,"slug":579,"hasResults":11,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":585,"targetDuration":587,"studyType":124,"phases":4,"briefSummary":588,"conditions":589,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":141},"100541523","allergy-asthma-and-atopic-eczema-in-finland-100541523","NCT06330974","Allergy, Asthma, and Atopic Eczema in Finland","Allergy, Asthma, and Atopic Eczema in Finland - A Nationwide Study on Prevalence, Comorbidities, Treatment and Economic Burden","FinnATOPY","Inclusion\u002FExclusion Criteria ---\\> https:\u002F\u002Fwww.finnatopy.fi\u002Fmethods",{"count":586,"type":21},2000000,"7 Years","The summary is available at --\\> https:\u002F\u002Fwww.finnatopy.fi\u002Fsummary",[330,493,27,590,492,591],"Rhinitis, Allergic","Allergen Immunotherapy","2024-03-19",{"date":594,"type":44},"2024-03-26",{"date":596,"type":21},"2024-10",{"date":598,"type":21},"2034-12",{"name":600,"class":82},"Tampere University",{"id":602,"slug":603,"hasResults":11,"nctId":604,"briefTitle":605,"officialTitle":605,"acronym":606,"eligibilityCriteria":607,"healthyVolunteers":178,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":608,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":609,"conditions":610,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":141},"100535217","systems-level-analyses-of-immune-dysregulation-100535217","NCT06248957","SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION","SAID","Inclusion Criteria:\n\nPatients of all ages seeking care or being referred for suspected immune dysregulation or with a known immune-mediated disease and failing to respond to standard therapy\n\nExclusion Criteria:\n\nHealthy control individuals will be excluded on the basis of having a diagnosis of an immune mediated disorder, immunomodulatory treatment or current infection or cancer.",{"count":302,"type":21},"The aim of the SAID study is to create a national resource in Sweden to enable comprehensive immunological analyses of an extremely complex and clinically challenging group of individuals with variable forms of immune system dysregulation. We hope to establish a biobank of primarily blood and fecal samples from children and adults, with confirmed or suspected immune dysregulation, as well as age- and sex- matched healthy controls, for comparisons of immune cell\u002Fmediator alongside various clinical presentations of these immunological diseases as well as microbiome samples as possible a possible modifier of clinical presentations. The project will also include the establishment of a national database with deep immunological data, treatment and clinical outcomes for these patients, accessible to participating researchers and clinicians.",[611,612,613,27,614],"Immunodeficiency","Autoimmune Diseases","Autoinflammatory Syndrome","Dysregulated Host Response","2024-01-31",{"date":617,"type":44},"2024-02-08",{"date":619,"type":44},"2024-01-01",{"date":621,"type":21},"2031-12-31",{"name":623,"class":82},"Karolinska Institutet",{"id":625,"slug":626,"hasResults":11,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":4,"eligibilityCriteria":630,"healthyVolunteers":178,"sex":16,"minAge":18,"maxAge":631,"enrollmentInfo":632,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":634,"conditions":635,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":141},"100473812","a-follow-up-study-with-children-who-participated-in-the-tempo-study-in-their-first-year-of-life-100473812","NCT05449756","A Follow-up Study With Children Who Participated in the TEMPO Study in Their First Year of Life","A Virtual, Decentralised Observational Follow-up Study Investigating Feeding Patterns in Infancy and the Associated Parent-reported Allergic Manifestations, Allergies and Infections in Childhood.","Inclusion Criteria:\n\n* Subjects are eligible to participate in the TEMPO Follow-Up study in case:\n* they completed the final (12 months) visit in the TEMPO study.\n* parents agree that their contact details will be shared with a third party for study purposes.\n* parents agree that data collected in the TEMPO study will be used in the TEMPO Follow-Up study.\n* parents provide written informed consent for participation in the TEMPO Follow-Up in accordance with local law.\n\nExclusion Criteria:\n\n* Parents who do not have a smartphone, tablet or personal computer with internet access.","10 Years",{"count":633,"type":21},705,"This is a follow-up study of a randomised clinical trial, called TEMPO (a double-blind randomized clinical trial investigating infant formula and human breast milk consumption), in which infants participated in their first year of life. The investigators like to know if these children develop allergies or infections in childhood and whether their feeding pattern in infancy plays a role.",[27,342],"2023-12-04",{"date":638,"type":44},"2023-12-11",{"date":640,"type":44},"2023-05-30",{"date":642,"type":21},"2029-03-31",{"name":644,"class":51},"Nutricia Research"]